Jinzhong (“JZ”) Zhang serves as the Chairman of the Board. Dr. Zhang is the Co-founder and Chief Executive Officer (CEO) of the company. With 25 years in ophthalmic research and drug development, he has held senior leadership roles in both private and large global ophthalmology companies. Previously he served as Vice President of Preclinical Development at Graybug Vision, Senior Director of Preclinical Development at Santen, and Director of Preclinical Pharmacology at Bausch & Lomb. Dr. Zhang received his Bachelor’s and Master’s degrees at Peking University and PhD in Molecular Biology through a joint program between Peking University and Kyoto University, served as an Assistant Professor of Ophthalmology and Medicine at Case Western Reserve University and Professor of Molecular Biology at Nankai University, and served as Principal Investigator on research awards sponsored by the National Eye Institute of the National Institutes of Health (NIH) and the National Natural Science Foundation of China.
Mr. Stephen Lin is a Partner with Lilly Asia Ventures. Prior to joining Lilly Asia Ventures, he most recently worked at GlaxoSmithKline (Great China), covering M&A and product licensing. Prior to that, he managed the marketing of a core product at Merck Serono (China). In Sanjiu Medical & Pharmaceutical, he set up and headed the Strategic Development Department. Stephen holds Master of Science in Medicinal Chemistry and Bachelor in Pharmaceutical Chemistry, both from China Pharmaceutical University, and an MBA degree from China Europe International Business School. He is also a Licensed Pharmacist in China.
Dr. Ting Xie is from Hillhouse BioVenture, which focuses on the investment of cutting-edge life science technologies and new therapies globally. Dr. Xie serves as a Board Member at various biotech companies. Prior to Hillhouse Capital he worked for a healthcare specialized private equity fund HealthCare Royalty Partners (HCR) in New York metro area and a Wall Street financial institution Alliance Bernstein covering biotech and specialty pharma. He obtained a PhD degree in Chemistry and Chemical Biology, Biological Chemistry and Molecular Pharmacology from Harvard University, and Bachelor of Science degree from Tsinghua University.
Dr. Marietta Wu is Managing Director of Quan Capital, a life sciences venture fund with offices in China and US, and deep expertise in cross-border value creation and global investments. She is a founding member of Zai Lab and served as COO and Director of the company prior to Quan Capital. Zai Lab is a NASDAQ listed company widely recognized as a leader in bringing innovative and transformative medicines to China. Over the past decade, Dr. Wu has been active in cross-border ventures and value creation in the life sciences industry. She was Managing Director at Burrill & Company, leading Burrill’s investments and operation in Greater China, focusing on venture capital investing in China and Taiwan related life sciences opportunities. She also served as acting COO of Waterstone, a specialty pharmaceutical company with key operations in China. Prior to her focus on healthcare investments and company building, Dr. Wu was Director of Strategy at Edwards Lifesciences. She also held various financial and business development positions at Eli Lilly & Company. Dr. Wu received her medical degree from Shanghai Jiaotong University School of Medicine (formerly Shanghai Second Medical University), a Ph.D. in Medical Sciences from Medical College of Ohio, and an MBA from the University of Michigan Ross School of Business.